Wendy's Board Rejects $7.35/Share Trian-Led Bid, Adopts Poison Pill
WEN sits 25% above its 52-week low of $5.94.
Summary
The independent directors unanimously turned down the Investor Group's $7.35-per-share cash offer, a bid worth $1.4 billion, saying it substantially undervalues Wendy's and the upside they expect from Dave's Way, the turnaround plan unveiled with today's Q3 release. The board also adopted a one-year shareholder rights plan effective immediately, with rights exercisable if any person or group crosses 15% without board approval; it expires November 3, 2027. The board cited that the Investor Group declined a customary standstill agreement. Wendy's said it has evaluated the investment needs of Dave's Way and is confident it has the financial capacity to execute the strategy, pointing to about $413 million in cash and $174 million of free cash flow year-to-date. This is a hard rejection, not a negotiating pause — the $7.35 bid is now off the table unless Trian returns with a higher number or goes hostile. The poison pill raises the cost of any creeping control play, and the stock at $7.45 already sits above the bid, so the market has been pricing a bump. Watch the 8:30 a.m. ET earnings call for Dave's Way details and any commentary on the bid.
At the time of this announcement, WEN was trading at $7.45 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $5.94 to $10.12. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: PR Newswire.